2023 Fiscal Year Final Research Report

Stady for mechanisms that molecularly-targeted therapy with Nivolumab augments chemotherapy efficiency on patients with chemotherapy-resistant head and neck cancers

Research Project

PDF

Project/Area Number	21K10150
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Review Section	Basic Section 57060:Surgical dentistry-related
Research Institution	Asahi University
Principal Investigator	KOSUKE NAGANAWA 朝日大学, 歯学部, 講師 (50712452)
Co-Investigator(Kenkyū-buntansha)	村松泰徳朝日大学, 歯学部, 教授 (30247556) 高山英次朝日大学, 歯学部, 准教授 (70533446) 梅村直己朝日大学, 歯学部, 講師 (80609107)
Project Period (FY)	2021-04-01 – 2024-03-31
Keywords	頭頚部腫瘍 / 分子標的薬 / 化学療法
Outline of Final Research Achievements	There are cases for Nivolumab-augmented chemotherapy efficiency on patients with chemotherapy-resistant head and neck cancers (HNCs). HNCs, Nivolumab and anticancer drugs, all modulate the immunities on patients. It is impossible human HNC cells transplant into a mouse with normal healthy immunities. Also it is difficult to study the mechanisms of anti-tumor immunities on immunodeficiency nude mice implanted with human HNC. In this stady, the cisplatin-resistant cells were established generated from the murine HNC cell line. And then, morphologies, expressed molecules, and migrated capacities and invasive activities were characterized on anticancer drug-resistant HNC cells. Moreover, the murine model with normal healthy immunities and syngeneic transplanted with anticancer drug-resistant HNC cells were established, and modulated immunities were investigated on mice transplanted with anticancer drug-resistant cells. (manuscript in preparation).
Free Research Field	頭頚部癌
Academic Significance and Societal Importance of the Research Achievements	本動物モデルは、患者HNCにおいてニボルマブによる分子標的療法後に化学療法が奏功する仕組みを検討するに有効である。本動物モデルを用いた本研究を引き続き発展させることで、単に患者の免疫能への影響やその仕組み明らかにするのみならず、治療後のQOL改善および様々な疾病の予防や治療に有益な新規の知見を与えると期待される。